Tenderwize
Retour à la recherche

Non-exclusive agreements for medicinal products containing Roxadustat (ATC B03XA05) via an open-house model

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline May 31, 2028 · 642 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Vereinbarungen über Arzneimittel mit dem Wirkstoff Roxadustat (ATC-Code: B03XA05) im Wege eines Open-House-Modells

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

30 / 100

Facteurs de risque

No guaranteed volumes; actual demand depends on patient numbers, prescribing behavior, and pharmacy stocking.

The agreement may be terminated early if the buyer concludes exclusive agreements, typically 8-12 months after publicat...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until May 2028
  • Non-exclusive supply of medicinal products containing Roxadustat (ATC B03XA05)
  • Open-house model allowing any qualified pharmaceutical company to participate
Afficher le résumé complet

This notice announces a non-exclusive open-house model agreement for pharmaceutical products containing Roxadustat (ATC B03XA05), organized by AOK PLUS for the regions of Saxony and Thuringia, Germany. The agreement has no guaranteed volumes, no exclusivity, and allows any qualified pharmaceutical company to join during the participation period. The procedure is not a public procurement under EU directives but a voluntary transparency measure. Submissions are accepted periodically until 31 May 2028, with the first deadline on 30 April 2026.

Risques

No guaranteed volumes; actual demand depends on patient numbers, prescribing behavior, and pharmacy stocking.

The agreement may be terminated early if the buyer concludes exclusive agreements, typically 8-12 months after publicat...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical company as defined in §4(18) AMG
  • Must have a registered office within the EU/EEA or Germany
  • Must accept the non-exclusive, no-negotiation open-house model

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No explicit award criteria in provided data; award is based on acceptance of terms and conditions.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-exclusive agreements for medicinal products containing Roxadustat (ATC B03XA05) via an open-house model

Non-exclusive framework agreement for the supply of Roxadustat (ATC B03XA05) under an open-house model. No minimum purchase quantities, no exclusivity, and individual negotiations are not conducted. The agreement ends no later than 31 May 2028.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

May 2026 - May 2028

Catégorie

Pharmaceutical products

Critères d'attribution

No explicit award criteria in provided data; award is based on acceptance of terms and conditions.

Date limite

Deadline May 31, 2028

Détails de la procédure

Date de publication
29 Mar 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
216077-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30